Monoclonal Antibody Service

About Monoclonal Antibody Service

Unlike polyclonal antibodies, which are produced from polyclonal populations of host antibody-producing cells, a monoclonal project requires the collection of the antibody producing cells themselves (lymphocytes). The lymphocytes are immortalized and screened using antigen to select for clones that recognize the antigen. These clones are then expanded and stabilized. The resulting monoclonal antibody is an exact copy of one original antibody and can be reproduced in unlimited quantities.

Monoclonal Antibody Service phage display is the most commonly used method for the in vitro selection of monoclonal antibodies. This is because it allows researchers to create a physical link between the phenotype (displayed peptide) and genotype (DNA sequence encoding the displayed peptide).

Introduction to Custom Antibody Production

Monoclonal antibodies (mAbs) are laboratory-engineered molecules that specifically bind to target antigens, mimicking the way our immune system attacks unwanted cells such as cancer cells. They can be used on their own as diagnostic tools or modified to carry drugs or other toxins directly to tumors through antibody-drug conjugates. Currently, more than a dozen monoclonal antibodies are undergoing clinical trials to treat various cancers.

Monoclonal antibodies can be given by injection under the skin, usually in the abdomen or thigh. Common side effects include infusion reaction, which is when your body’s immune system responds to the treatment and can cause a variety of symptoms such as rash, fever, chills, rigors/chills, breathing difficulties or changes in blood pressure and heart rate. The most serious reactions that can occur during or shortly after monoclonal antibody therapy are anaphylaxis, cytokine release syndrome and serum sickness.